NeuMedics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $215K
Latest Deal Amount
  • Investors
  • 1

NeuMedics General Information

Description

Developer of a topically administered micro emulsion eye drop to treat Diabetic Macular Edema (DME). The company has created a proprietary new compound (NM108) that can be used as a preventative treatment to delay the onset of Alzheimer's disease (AD) dementia symptoms.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Drug Delivery
Biotechnology
Primary Office
  • 5223 SouthWest Jacobsen Road
  • Seattle, WA 98116
  • United States
+1 (206) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuMedics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 04-May-2015 $215K 0000 Completed Generating Revenue
1. Angel (individual) 05-May-2009 0000 0000 Completed Startup
To view NeuMedics’s complete valuation and funding history, request access »

NeuMedics Executive Team (3)

Name Title Board Seat Contact Info
Iain Duncan Co-Founder & Chief Executive Officer
Barbara Wirostko MD Member of Scientific Advisory Board & Clinical Advisor
William Schwieterman MD Board Member, Chief Medical Officer, Vice President and CMO
To view NeuMedics’s complete executive team members history, request access »

NeuMedics Board Members (1)

Name Representing Role Since
William Schwieterman MD Self Board Member, Chief Medical Officer, Vice President and CMO 000 0000
To view NeuMedics’s complete board members history, request access »

NeuMedics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Washington State Life Sciences Discovery Fund Government 000 0000 000000 0
To view NeuMedics’s complete investors history, request access »